Johnson & Johnson Innovation kick started 2018 by striking collaborative agreements with 15 different organizations and companies to address areas of high unmet medical need in neuroscience, oncology and other areas.

San Diego-based Arena Pharmaceuticals announced that it had created an independent, privately held drug discovery incubator called Beacon Discovery.

LONDON and BOSTON, November 30, 2015 /PRNewswire/ — Heptares Therapeutics (“Heptares”), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines […]

Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines directed at […]

AstraZeneca expanded its push into cancer immunotherapy on Thursday by striking a deal potentially worth more than $500 million with Sosei’s biotech unit Heptares, giving it rights to an experimental treatment. AstraZeneca said it would pay an initial $10 million for exclusive global rights to HTL-1071, a so-called adenosine A2A receptor antagonist, and could pay […]

LONDON and BOSTON, August 6, 2015 /PRNewswire/ — Heptares Therapeutics (“Heptares”), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to […]